About Zaltenibart (OMS906) Zaltenibart is an investigational human monoclonal antibody targeting mannan-binding lectin ... activator of the complement system’s alternative pathway.
Objective: Newborns are highly susceptible to bacterial sepsis. Mannan-binding lectin (MBL), M-, L- and H-ficolin recognize microorganisms and activate the complement system via MBL-associated ...
Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback